

ONCE-YEARLY *Uninterrupted*
SUPPRELIN[®] LA
(histrelin acetate) subcutaneous implant

Childhood. Uninterrupted.

When discussing a treatment for your child with central precocious puberty (CPP)

Five good reasons to ask your doctor about SUPPRELIN[®] LA

- 1** FDA approved, with proven hormone (LH) suppression in 100% of treated children, and 97% to 100% sex hormone suppression*
- 2** The **longest-acting** single-dose treatment for CPP†
- 3** Unique delivery of **continuous, each-and-every day** CPP treatment – **for twelve full months**
- 4** **No deep muscular injection** required
- 5** **Selected by doctors and parents for over a decade, with thousands of implants used to treat patients each year in the US**

Monitoring Progress:

†Keep all scheduled visits to the doctor. The doctor will do regular exams and blood tests to check for signs of puberty. Your child's healthcare professional may recommend that he or she avoid heavy play or exercise for about a week after insertion of SUPPRELIN[®] LA. The doctor will decide when to end treatment so that puberty can begin as normal.

Talk to your doctor today

Ask about how eligible patients may save up to \$2,000 off each SUPPRELIN[®] LA prescription after a \$10 copay. Restrictions apply.‡

Demonstrated in a Clinical Study:

*A clinical study was conducted in 36 children (33 females and 3 males), 4.5 to 11.6 years of age, to evaluate the efficacy and safety of SUPPRELIN[®] LA for the treatment of CPP. Efficacy assessments measured the suppression of gonadotropins (luteinizing hormone [LH] and follicle-stimulating hormone [FSH]) and gonadal sex steroids (estrogen in girls and testosterone in boys) on treatment. The primary measure of efficacy was LH suppression. The initial duration of therapy was 12 months (plus a 1-month follow-up period). At the 12-month visit, all patients had their initial implant from Day 1 removed and those patients who continued to meet all efficacy and safety parameters (as determined by the investigators) were eligible to receive a new SUPPRELIN[®] LA implant, with the possibility of rolling over into multiple 12-month extension phases.

†Offer good only in the USA and void where prohibited or otherwise restricted by law. Offer not valid for prescriptions that may be reimbursed under a federal or state healthcare program, including Medicare, Medicaid, or any other federal or state healthcare programs, including any state medical pharmaceutical assistance programs. Patients over the age of 18 are not eligible. Endo Pharmaceuticals Inc. has the right to rescind, revoke, or amend this program without notice. This offer is not transferable.

WHAT IS SUPPRELIN[®] LA?

- SUPPRELIN[®] LA is an implanted gonadotropin releasing hormone (GnRH) medicine used for the treatment of children with central precocious puberty (CPP).
- It is not known if SUPPRELIN[®] LA is safe and effective in children under 2 years of age.

IMPORTANT SAFETY INFORMATION ABOUT SUPPRELIN[®] LA

- SUPPRELIN[®] LA should not be taken if your child is allergic to gonadotropin releasing hormone (GnRH), GnRH agonist medicines, or any ingredients in the SUPPRELIN[®] LA implant, or is pregnant or becomes pregnant. SUPPRELIN[®] LA can cause birth defects or loss of the baby. If your child becomes pregnant, call your doctor.
- In the first week of treatment, SUPPRELIN[®] LA can cause an increase in some hormones. During this time, you may notice more signs of puberty in your child, including light vaginal bleeding and breast enlargement in girls. Within 4 weeks of treatment, you should see signs in your child that puberty is stopping.

Please see Important Safety Information on next page.

Please [click here](#) for full Prescribing Information, including Medication Guide.

http://www.endo.com/File%20Library/Products/Prescribing%20Information/SUPPRELINLA_prescribing_information.html

To learn more, visit SupprelinLA.com

WHAT IS SUPPRELIN® LA?

- SUPPRELIN® LA is an implanted gonadotropin releasing hormone (GnRH) medicine used for the treatment of children with central precocious puberty (CPP).
- It is not known if SUPPRELIN® LA is safe and effective in children under 2 years of age.

IMPORTANT SAFETY INFORMATION ABOUT SUPPRELIN® LA

- **SUPPRELIN® LA should not be taken if your child is allergic to gonadotropin releasing hormone (GnRH), GnRH agonist medicines, or any ingredients in the SUPPRELIN® LA implant, or is pregnant or becomes pregnant.** SUPPRELIN® LA can cause birth defects or loss of the baby. If your child becomes pregnant, call your doctor.
- In the first week of treatment, SUPPRELIN® LA can cause an increase in some hormones. During this time, you may notice more signs of puberty in your child, including light vaginal bleeding and breast enlargement in girls. Within 4 weeks of treatment, you should see signs in your child that puberty is stopping.
- Some people who had SUPPRELIN® LA placed in their arm have had the implant come through the skin (extrusion). **Call your child's doctor right away if the SUPPRELIN® LA implant comes through the skin.**
- Some people taking GnRH agonists like SUPPRELIN® LA have had new or worsening mental (psychiatric) problems including depression. Mental (psychiatric) problems may include emotional symptoms such as crying, irritability, restlessness (impatience), anger, and acting aggressive. **Before your child receives SUPPRELIN® LA, tell the doctor if they have a history of mental problems. Call your child's doctor right away if your child has any new or worsening mental symptoms or problems while taking SUPPRELIN® LA.**
- Some people taking GnRH agonists like SUPPRELIN® LA have had seizures. The risk of seizures may be higher in people who have a history of seizures, epilepsy, brain or brain vessel (cerebrovascular) problems or tumors, or who are taking a medicine that has been connected to seizures such as bupropion or selective serotonin reuptake inhibitors (SSRIs). Seizures have also happened in people who have not had any of these problems. **Before your child receives SUPPRELIN® LA, tell the doctor if they have a history of these problems, as well as all the medicines they take. Call your child's doctor right away if your child has a seizure while taking SUPPRELIN® LA.**
- Your child's doctor should do tests to make sure your child has CPP before treating with SUPPRELIN® LA. SUPPRELIN® LA lasts for 12 months. One implant will give the medicine for 12 months. After 12 months, SUPPRELIN® LA must be removed. The doctor may insert a new SUPPRELIN® LA at this time to continue treatment.
- SUPPRELIN® LA is placed under the skin of the inside of the upper arm. The doctor will numb the arm of your child, make a small cut, and then place SUPPRELIN® LA under the skin. The cut may be closed with stitches or surgical strips and covered with a pressure bandage.
- Your child should keep the arm clean and dry and should not swim or bathe for 24 hours after receiving the SUPPRELIN® LA implant. The bandage can be removed after 24 hours. **Do not** remove any surgical strips. They will fall off on their own in a few days. Your child should avoid heavy play or exercise that uses the implanted arm for 7 days. You and your child should routinely check the insertion site until the cut is healed. After the cut has healed, your child can go back to his or her normal activities. The doctor will give you complete instructions.
- Keep all scheduled visits to the doctor. Your child's doctor will do regular exams and blood tests to check for signs of puberty. Sometimes the doctor will have to do special tests, such as ultrasound or MRI, if the SUPPRELIN® LA implant is difficult to find under your child's skin.
- The most common side effects of SUPPRELIN® LA are skin reactions at the place where the implant is inserted. These reactions may include pain, redness, bruising, soreness, and swelling in and around the implant site. Call your child's doctor if your child has bleeding, redness, or severe pain where the implant was inserted.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088.

Please [click here](#) for full Prescribing Information, including Medication Guide.

http://www.endo.com/File%20Library/Products/Prescribing%20Information/SUPPRELINLA_prescribing_information.html

SUPPRELIN® LA
(histrelin acetate) subcutaneous implant

 **endo**
pharmaceuticals
an endo international company

Rx Only

SUPPRELIN® is a registered trademark of Endo International plc or one of its affiliates.
© 2019 Endo Pharmaceuticals Inc. All rights reserved. Malvern, PA 19355
SP-05326/February 2019 www.supprelinla.com 1-800-462-ENDO (3636)